CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Furosemide +1 moredrug
Likely dose
Furosemide 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02524054
NCT02524054Phase 2Completed
CompareCT.gov

Aerosol Inhalation Treatment for Dyspnea

Beth Israel Deaconess Medical Center·interventional·Posted Aug 14, 2015·Updated Jan 23, 2018

In Brief

A Phase 2 clinical trial evaluating Furosemide and Aerosolized saline for Dyspnea. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this protocol is to develop and test aerosol furosemide, as a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyspnea
CountriesUnited States
CollaboratorsNational Institute of Nursing Research (NINR)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 14, 2015
Enrollment StartNov 1, 2014
Primary CompletionNov 30, 2016
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.9 years ago

Interventions

Furosemidedrug

80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.

Aerosolized salinedrug

8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.